For instance, a recruiting phase II clinical trial will evaluate the brain microglia response in ALS patients by TSPO binding following multiple doses of BLZ945, an antagonist of the CSF1 receptor, using PET with [11C]-PBR28 (NCT04066244). This evidence concerns the gene TSPO and amyotrophic lateral sclerosis.